AlphAIalphai — Financial news for AI agents
investing.comAUG 212 min read$NUVB

Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating

Cantor Fitzgerald initiated Nuvation Bio (NYSE:NUVB) with an overweight rating and a $12 price target, citing its two targeted therapies. The firm estimates peak sales of $965M for Ibtrozi and $1.9B for safusidenib. NUVB reported Q2 2026 revenue of $31.7M, beating estimates but with a wider loss per share. The stock is up 149% over the past year.

Original reporting
investing.com
Published Aug 21, 2026, 11:13 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 1:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$NUVB
Bullish
medium confidence
Mentioned
$NUVB
Relevance
6/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$NUVBBullishMed
01

Why it matters

Analyst upgrades provide fresh catalyst; revenue beat adds credibility to growth forecasts.

02

Market read

New analyst ratings and price targets create actionable trading ideas for NUVB.

03

What to watch

High cash burn and reliance on two drugs could limit upside.

Relevance 6/10Novelty 6/10Timing: today

Background

Cantor Fitzgerald and JPMorgan both initiated coverage on Nuvation Bio, highlighting its two oncology therapies.

Company-level read

Ticker impact

$NUVBBullishMedium confidence
Context

Cantor Fitzgerald initiated coverage with an overweight rating and a $12 price target, citing revenue beat and drug pipeline potential.

Expected impact

Potential upside of 70%+ if target is reached.

Evidence & confidence

New rating and price target provide a concrete catalyst for traders.

Market effects

Sector

Positive outlook for oncology biotech sector.

Regional

US biotech stocks may see modest lift.

Global

Limited to investors tracking US-listed biotech.

Counterpoint

What could challenge this read

Rating may be premature given widened loss per share.

Key entities

  • company
    Nuvation Bio Inc

    Commercial-stage oncology biotech (NYSE:NUVB).

  • research_firm
    Cantor Fitzgerald

    Initiated coverage with overweight rating.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 22
$NUVBMed

JPMorgan sees 100% upside in overlooked cancer drug stock

JPMorgan initiated coverage of Nuvation Bio (NUVB) with an Overweight rating and a $13 price target, implying 100% upside. The bank cited strong sales of IBTROZI, a lung cancer drug launched in 2026, and potential from safusidenib, an experimental brain tumor drug. Nuvation reported Q2 2026 revenue of $31.7M, beating estimates, but still operating at a loss. The stock has fallen 18% YTD but gained 8% in the past five days.

yahoo.com3 min
AUG 21
$NUVBHighAI 8/10

Why is Nuvation Bio stock rallying today?

Nuvation Bio (NUVB) stock rose 2.8% to $7.02 after the FDA granted Fast Track Designation to safusidenib, its therapy for IDH1-mutant glioma, citing Phase 2 study data. Cantor Fitzgerald initiated coverage with an Overweight rating and $12 price target, projecting peak sales of $965M for IBTROZI and $1.9B for safusidenib. The broader market also showed gains.

investing.com2 min
AUG 21
$NUVBHigh

Nuvation Bio stock rises after Cantor starts at Overweight

Nuvation Bio (NUVB) shares rose 2.7% after Cantor Fitzgerald initiated coverage with an Overweight rating and $12 price target. Analyst Li Watsek highlighted two therapies, Ibtrozi and safusidenib, with peak sales estimates of $965M and $1.9B respectively, suggesting significant upside. Cantor also noted potential strategic interest in the company.

investing.com1 min
AUG 13
$NUVBMedAI 8/10

Nuvation Bio (NUVB) Q2 2026 Earnings Call Transcript

Nuvation Bio (NUVB) reported Q2 2026 revenue of $31.7M, including $23.2M IBTROZI product revenue and $8.5M collaboration and license revenue. IBTROZI net product revenue grew 25% QoQ to $23.2M, with 160 new patient starts. Net loss was $62.8M. Cash and marketable securities were $661M. The company raised $279.1M via convertible notes and expects a potential $30M Eisai EU milestone in 1H 2027.

fool.com10 min